Clinical trials: CYP19
Breast Cancer, Pain
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
Postmenopausal women who have hormone receptor positive breast cancer are typically treated with aromatase inhibitor medications, which substantially decrease the amount of estrogen produced by their bodies.
- Conditions
- Breast Cancer, Pain, Arthralgia
- Trial name
- NCT01814397
- Testing
- Anastrozole, exemestane, letrozole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer
Oral Aromatase Inhibitors Modify the Gut Microbiome
The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
- Trial name
- NCT05030038
- Testing
- Fecal swab collection, Blood samples
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Hypogonadism, Severe Obesity
Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)
After the age of 40, there is a gradual decline in the production of testosterone. Among obese men, the decline in testosterone levels is exacerbated by the suppression of the hypothalamic-pituitary-gonadal axis by…
- Trial name
- NCT02959853
- Testing
- Anastrazole, weight loss
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Breast Cancer, Osteoporosis
Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?
Research Question: Do Aromatase Inhibitors Decrease Intestinal Calcium Absorption? Study Design: Postmenopausal women with early stage breast cancer initiating aromatase inhibitor adjuvant therapy will participate in this…
- Conditions
- Breast Cancer, Osteoporosis, Osteopenia, Fracture
- Trial name
- NCT00766532
- Testing
- Aromatase Inhibitor
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Breast Neoplasms, Venous Thromboembolism
Hemostatic Profiles of Endocrine Therapies for Breast Cancer
The aim of this prospective cohort study is to evaluate the modifications of the biological hemostatic profile associated with the use of endocrine therapy in women with breast cancer (tamoxifen or aromatase inhibitors).
- Trial name
- HEMOBREAST (NCT03381963)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Geneva
Breast Cancer, Musculoskeletal Disease
Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients
The third generation oral aromatase inhibitors (AIs) are increasingly being used in the management of estrogen receptor positive breast cancer.
- Trial name
- NCT01809171
- Testing
- Vitamin D3
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients
To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.
- Trial name
- SEAT (NCT02440230)
- Testing
- OFS + Anastrozole, OFS + Exemestane
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Neoplasms
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with estrogen receptor positive (ER+), human…
- Trial name
- NCT02374099
- Testing
- CC-486, Fulvestrant
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 97 people
- Sponsor
- Celgene
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
This phase II trial studies how well carbon dioxide fractional (CO2RE) laser works in treating participants with stage 0-III hormone receptor-positive breast cancer with vulvovaginal atrophy associated with dryness, inflammation…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT03666819
- Testing
- Carbon Dioxide Fractional Laser, Questionnaire Administration
- Sponsor
- Mayo Clinic
Breast Cancer
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
RATIONALE: Studying changes in breast density and blood hormone levels in women receiving anastrozole or exemestane for breast cancer may help doctors learn more about the long-term effects of treatment and may help the study of…
- Trial name
- NCT00516698
- Testing
- polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis
- Where
- 180 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Vaginal Atrophy, Postmenopausal Symptoms
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
The purpose of this research is to gather information on the safety and effectiveness of Intrarosa®, also known as Dehydroepiandrosterone (DHEA), and prasterone.
- Conditions
- Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
- Trial name
- NCT04493333
- Testing
- Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
Breast Cancer
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
This is a retrospective, observational study that will document the treatment and monitoring patterns and clinical outcomes of patients diagnosed with HR+/HER2- a/mBC who received Palbociclib combination therapy with aromatase…
- Trial name
- NCT04498481
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Biology Guided Therapy for Breast Cancer for ER Positive
There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor.
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- SPOCK (NCT04965688)
- Testing
- Biopsy-Guided Therapy Selection
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services
Breast Neoplasm Female, Arthralgia
Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias
This is a single center, double-blinded, placebo-controlled, randomized Phase II trial to determine whether oral hyaluronic acid will prevent aromatase inhibitor (AI)-associated arthralgias.
- Trial name
- NCT03384095
- Testing
- Hyaluronic Acid (HA)
- Where
- 4 sites in United States
- Sponsor
- Erin Newton
HER2-Positive Breast Carcinoma
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.
- Trial name
- NCT06557057
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Vulvar Atrophy, Breast Cancer
Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors
VAGINAL PRASTERONE in the treatment of VAGINAL ATROPHY IN PATIENTS WITH BREAST CANCER TREATMENT WITH AROMATASE INHIBITORS (VIBRA STUDY)
- Conditions
- Vulvar Atrophy, Breast Cancer, Genitourinary Syndrome of Menopause
- Trial name
- VIBRA (NCT04705883)
- Testing
- Prasterone (DHEA), Micronized
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Clinic of Barcelona
Breast Cancer
500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI
500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI
- Trial name
- NCT03695341
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Breast Cancer, Arthralgia
Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms
Early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease.
- Trial name
- NCT02118636
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Lynn Henry
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Brest Cancer ER+ and HER2 Negative
De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer
This study is a randomized, open-label, phase II trial designed to evaluate whether alternate-day dosing of letrozole preserves antiproliferative activity compared with standard daily dosing in postmenopausal women with estrogen…
- Trial name
- DELTA (NCT07866430)
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Montefiore Medical Center